Anavex CEO to Participate in Brean Capital 2013 Life Sciences Summit

New York, NY — November 21, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company engaged in the development of novel drug candidates for the treatment of Alzheimer’s disease, CNS and oncology, today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will participate…

Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of Alzheimer’s Disease

Study Presented at CNS Summit 2013 Suggests ANAVEX 2-73 Will Have Clinically Detectable and Meaningful Effect in Alzheimer’s Disease, Especially When Combined With Aricept® New York, NY — November 18, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) presented new data from a study evaluating ANAVEX 2-73 in a computer simulation…

Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer’s Disease

Data Presented at Society for Neuroscience 2013 Annual Meeting New York, NY — November 12, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) is pleased to announce that new study data showed ANAVEX 2-73 to be effective in counteracting the progression of Alzheimer’s disease under chronic treatment in a transgenic mouse model…

Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013

New York, NY — November 7, 2013 — Anavex Life Sciences Corp. (OTCQB: AVXL) is pleased to announce that its President and Chief Executive Officer Christopher U. Missling, PhD, will be presenting new clinical predication data supporting its investigational compound, ANAVEX 2-73, as a potential therapeutic for the treatment of Alzheimer’s disease.  The data will…

Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of Alzheimer’s Disease

New York, NY — November 4, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) announces that issue 38 (2013) of the international scientific journal Neuropsychopharmacology contains a report demonstrating that ANAVEX 2-73 dose-dependently blocks Tau and amyloid-beta (“amyloid”) proteins and memory deficit in a mouse model of Alzheimer’s disease (AD). A reduction in…